Survodutide (BI 456906) 10mg/Vial,10Vials/Kit (Box)

A differentiated glucagon/GLP-1 receptor dual agonist targeting obesity and MASH
 

Survodutide (BI 456906), licensed to Boehringer Ingelheim, is an investigational long-acting, glucagon/GLP-1 receptor dual agonist for once-weekly subcutaneous administration. Activating the glucagon and GLP-1 receptors simultaneously may reduce body weight by both increasing energy expenditure and reducing food intake.

The molecule is designed to leverage the body weight reduction and glycemic control of GLP-1 receptors with some activity on the glucagon receptors, which are present in the liver.